Margaret Rosenfeld

List of Publications by Year
in descending order

208 papers	18,202 citations	17776 65 h-index	16791 127 g-index
210 all docs	210 docs citations	210 times ranked	12917 citing authors

#	Article	IF	Citations
1	Comparing encounter-based and annualized chronic pseudomonas infection definitions in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 40-44.	0.3	3
2	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 529-539.	2.5	147
3	ERS/ATS technical standard on interpretive strategies for routine lung function tests. European Respiratory Journal, 2022, 60, 2101499.	3.1	323
4	Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa. Annals of the American Thoracic Society, 2022, 19, 1320-1327.	1.5	5
5	The effect of inhaled hypertonic saline on lung structure in children aged 3â€“6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 669-678.	5.2	20
6	Club cell secretory protein and lung function in children with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 811-820.	0.3	8
7	Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. Biometrical Journal, 2022, , .	0.6	0
8	Building for the Future: Establishment of the Primary Ciliary Dyskinesia Foundation Clinical Registry. , 2022, , .		0
9	Progression of Upper Airway Manifestations in Primary Ciliary Dyskinesia Throughout Childhood. , 2022, , .		0
10	Accounting for population structure in genetic studies of cystic fibrosis. Human Genetics and Genomics Advances, 2022, 3, 100117.	1.0	1
11	Relationship Between Genotype/Ultrastructural Defect and Neonatal Respiratory Distress in Primary Ciliary Dyskinesia. , 2022, , .		0
12	Performance and Usability of a New Mobile Phone Application in Assessing Respiratory Rate in Pediatric Patients. , 2022, , .		0
13	Factors Associated with Abnormal Lung Function in Adolescents With and Without HIV in Nairobi, Kenya. , 2022, , .		0
14	COMBATing airway inflammation in infants with cystic fibrosis. Lancet Respiratory Medicine,the, 2022, , .	5.2	0
15	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1239-1247.	2.5	13
16	Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 585-593.	2.5	67
17	Survey and electronic health recordâ€based medication use agreement in children with cystic fibrosis: A retrospective crossâ€sectional study. International Journal of Paediatric Dentistry, 2021, 31, 247-253.	1.0	0
18	Innovating and adapting in pediatric pulmonology and sleep medicine during the COVIDâ€19 pandemic: ATS pediatric assembly web committee consensus statement for initial COVIDâ€19 virtual response. Pediatric Pulmonology, 2021, 56, 539-550.	1.0	7

#	Article	IF	Citations
19	Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinology, Diabetes and Metabolism, 2021, 4, e00208.	1.0	4
20	Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Annals of the American Thoracic Society, 2021, 18, 266-272.	1.5	8
21	S63â€…Ivacaftor in 4- to <6-month-old infants with cystic fibrosis and a gating mutation: results of a 2-part, single-arm, Phase 3 study. , 2021, , .		1
22	Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Clinical Infectious Diseases, 2021, 73, 987-993.	2.9	4
23	Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 157-166.	1.4	11
24	Therapies Used for Primary Ciliary Dyskinesia in North American Children. , 2021, , .		0
25	Upper Airway Manifestations of Primary Ciliary Dyskinesia During Childhood. , 2021, , .		0
26	Relationship Between Genotype and Laterality Defects in Primary Ciliary Dyskinesia. , 2021, , .		0
27	Severity of Neonatal Respiratory Distress and Future Lung Function in Children with Primary Ciliary Dyskinesia. , 2021, , .		0
28	Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Clinical Infectious Diseases, 2021, 73, 1589-1596.	2.9	10
29	Health workersâ€™ perspectives of a mobile health tool to improve diagnosis and management of paediatric acute respiratory illnesses in Uganda: a qualitative study. BMJ Open, 2021, 11, e049708.	0.8	11
30	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. Journal of Cystic Fibrosis, 2020, 19, 114-118.	0.3	7
31	Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 407-414.	0.3	15
32	Resilience in adolescents and young adults with cystic fibrosis: A pilot feasibility study of the promoting resilience in stress managementÂintervention. Pediatric Pulmonology, 2020, 55, 638-645.	1.0	13
33	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Annals of the American Thoracic Society, 2020, 17, 1590-1598.	1.5	8
34	Pediatric lung function testing during a pandemic: An international perspective. Paediatric Respiratory Reviews, 2020, 36, 106-108.	1.2	9
35	Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Societyâ€“coordinated Task Force. Annals of the American Thoracic Society, 2020, 17, 1343-1351.	1.5	47
36	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatric Pulmonology, 2020, 55, 3400-3406.	1.0	8

#	Article	IF	Citations
37	Comparison of Longitudinal Clinical Outcomes in Primary Ciliary Dyskinesia and Cystic Fibrosis. , 2020, , .		0
38	Association of Genotype and Structural Lung Disease in a Cohort of Children with PCD. , 2020, , .		0
39	Comparison of Multiple Breath Washout and Spirometry in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis and Healthy Controls. Annals of the American Thoracic Society, 2020, 17, 1085-1093.	1.5	25
40	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2020, 2020, CD001912.	1.5	7
41	Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 190-198.	2.5	116
42	The expanding phenotype of OFD1â€related disorders: Hemizygous lossâ€ofâ€function variants in three patients with primary ciliary dyskinesia. Molecular Genetics & Genomic Medicine, 2019, 7, e911.	0.6	31
43	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	5.2	89
44	Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e70-e88.	2.5	1,812
45	Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 751-761.	0.8	0
46	Tidal Changes in Respiratory Resistance in Children with Cystic Fibrosis. , 2019, , .		0
47	Palivizumab and Long-term Outcomes in Cystic Fibrosis. Pediatrics, 2019, 144, e20183495.	1.0	4
48	Socioeconomic and Environmental Risk Factors for Pediatric Asthma in an American Indian Community. Academic Pediatrics, 2019, 19, 631-637.	1.0	8
49	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2â€“5â€¯years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.3	94
50	Climate change and lung health: presidential failure, professional responsibility. Thorax, 2019, 74, 627-628.	2.7	1
51	Associating antimicrobial susceptibility testing with clinical outcomes in cystic fibrosis: More rigor and less frequency?. Journal of Cystic Fibrosis, 2019, 18, 159-160.	0.3	1
52	Sensitivity of Multiple Breath Washout and Spirometry for Detection of Early Lung Disease in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis: A Multicenter Study. , 2019, , .		0
53	Initial Development of a Mobile Health Tool to Objectively Measure Respiratory Distress in Infants. , 2019, , .		1
54	Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatrics, 2019, 215, 164-171.e2.	0.9	16

#	Article	IF	Citations
55	Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens. Annals of the American Thoracic Society, 2018, 15, 702-709.	1.5	28
56	Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 197, e1-e19.	2.5	92
57	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	2.5	32
58	Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0â€“11 years. Journal of Cystic Fibrosis, 2018, 17, 680-686.	0.3	10
59	Treating Cystic Fibrosis Pulmonary Exacerbations: In the Hospital with a Physician or at Home under Your Own Supervision?. Annals of the American Thoracic Society, 2018, 15, 169-170.	1.5	0
60	Reply to Johnson: Improve Pulmonary Function Test Reporting. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 138-139.	2.5	0
61	Spirometry-Assisted High Resolution Chest Computed Tomography in Children: Is it Worth the Effort?. Current Problems in Diagnostic Radiology, 2018, 47, 14-18.	0.6	6
62	Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Annals of the American Thoracic Society, 2018, 15, 234-240.	1.5	37
63	Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 42-48.	1.5	24
64	Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 341-347.	0.3	38
65	Primary ciliary dyskinesia: keep it on your radar. Thorax, 2018, 73, 101-102.	2.7	5
66	Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6â€“20 years: A pilot study. Journal of Cystic Fibrosis, 2018, 17, 747-759.	0.3	9
67	Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 197, e24-e39.	2.5	285
68	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	5.2	205
69	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1177-1187.	2.5	75
70	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. Pediatrics, 2017, 139, .	1.0	52
71	Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations. Pediatrics, 2017, 139, .	1.0	48
72	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. Journal of Pediatrics, 2017, 181, S4-S15.e1.	0.9	572

#	Article	IF	Citations
73	Climate change and lung health: the challenge for a new president. Thorax, 2017, 72, 295-296.	2.7	5
74	Diagnosis of Cystic Fibrosis in Screened Populations. Journal of Pediatrics, 2017, 181, S33-S44.e2.	0.9	82
75	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2017, 4, CD001912.	1.5	33
76	Pseudomonas aeruginosa eradication: Finally moving the needle?. Journal of Cystic Fibrosis, 2017, 16, 309-310.	0.3	0
77	Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2017, 14, 1184-1196.	1.5	41
78	Elementary, My Dear Watson! The Accumulating Evidence for the Lung Clearance Index in Monitoring Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1131-1132.	2.5	3
79	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	5.2	243
80	S96â€...An open-label extension (ext) study of lumacaftor/ivacaftor (lum/iva) therapy in patients aged 6 to 11 years with cystic fibrosis (cf) homozygous for f508del-cftr. , 2017, , .		0
81	Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1463-1472.	2.5	450
82	Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infectious Diseases, 2017, 17, 411.	1.3	16
83	Lumacaftor/Ivacaftor in Patients Aged 6â€“11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 912-920.	2.5	138
84	Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 106.	0.8	30
85	Association of meteorological and geographical factors and risk of initialPseudomonas aeruginosaacquisition in young children with cystic fibrosis. Epidemiology and Infection, 2016, 144, 1075-1083.	1.0	19
86	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 386-391.	0.3	13
87	Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Annals of the American Thoracic Society, 2016, 13, 1305-1313.	1.5	138
88	Cystic Fibrosis Diagnosis and Newborn Screening. Pediatric Clinics of North America, 2016, 63, 599-615.	0.9	35
89	Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2â€“5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respiratory Medicine,the, 2016, 4, 107-115.	5.2	284
90	Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatric Pulmonology, 2016, 51, 115-132.	1.0	297

#	Article	IF	Citations
91	Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics, 2016, 137, .	1.0	140
92	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	0.9	44
93	An Official American Thoracic Society/European Respiratory Society Workshop Report: Evaluation of Respiratory Mechanics and Function in the Pediatric and Neonatal Intensive Care Units. Annals of the American Thoracic Society, 2016, 13, S1-S11.	1.5	29
94	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Journal of Pediatrics, 2015, 167, 1081-1088.e1.	0.9	63
95	Yoga as a Therapy for Adolescents and Young Adults with Cystic Fibrosis: A Pilot Study. Global Advances in Health and Medicine, 2015, 4, 32-36.	0.7	5
96	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	1.0	19
97	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 763-770.	1.0	94
98	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 932-939.	1.5	96
99	Clinical Features of Childhood Primary Ciliary Dyskinesia by Genotype and Ultrastructural Phenotype. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 316-324.	2.5	214
100	Pulmonary exacerbations and parentâ€reported outcomes in children <6 years with cystic fibrosis. Pediatric Pulmonology, 2015, 50, 236-243.	1.0	19
101	Fine Particulate Matter Exposure and Initial Pseudomonas aeruginosa Acquisition in Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 385-391.	1.5	57
102	WS01.5 An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with cystic fibrosis and a CFTR gating mutation: The KIWI study. Journal of Cystic Fibrosis, 2015, 14, S2.	0.3	6
103	Impact of Sustained Eradication of NewPseudomonas aeruginosaInfection on Long-term Outcomes in Cystic Fibrosis. Clinical Infectious Diseases, 2015, 61, 707-715.	2.9	66
104	Initial evaluation of the Parent Cystic Fibrosis Questionnaireâ€"Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis, 2015, 14, 403-411.	0.3	23
105	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	1.0	43
106	Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening. Pediatrics, 2015, 135, e1386-e1392.	1.0	78
107	Early Childhood Risk Factors for Decreased FEV1at Age 6-7 Years in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 150819115840007.	1.5	25
108	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 42-48.	1.0	59

#	Article	IF	Citations
109	Selection and Appropriate Use of Spirometric Reference Equations for the Pediatric Population. Respiratory Medicine, 2015, , 181-193.	0.1	0
110	Mutations in RSPH1 Cause Primary Ciliary Dyskinesia with a Unique Clinical and Ciliary Phenotype. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 707-717.	2.5	191
111	Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals of the American Thoracic Society, 2014, 11, 1640-1650.	1.5	197
112	Narrowing in on Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1082-1084.	2.5	5
113	Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 15-22.	0.6	14
114	Laterality Defects Other Than Situs Inversus Totalis in Primary Ciliary Dyskinesia. Chest, 2014, 146, 1176-1186.	0.4	192
115	Survey of clinical infant lung function testing practices. Pediatric Pulmonology, 2014, 49, 126-131.	1.0	32
116	Early childhood wheezing is associated with lower lung function in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 745-750.	1.0	21
117	Differential Geographical Risk of Initial Pseudomonas aeruginosa Acquisition in Young US Children With Cystic Fibrosis. American Journal of Epidemiology, 2014, 179, 1503-1513.	1.6	22
118	Evaluation of Microbial Bacterial and Fungal Diversity in Cerebrospinal Fluid Shunt Infection. PLoS ONE, 2014, 9, e83229.	1.1	21
119	Cri du Chat Syndrome and Primary Ciliary Dyskinesia: A Common Genetic Cause on Chromosome 5p. Journal of Pediatrics, 2014, 165, 858-861.	0.9	15
120	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 542-549.	0.3	15
121	The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry. Journal of Cystic Fibrosis, 2014, 13, 319-327.	0.3	41
122	Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis. Clinical Infectious Diseases, 2014, 59, 624-631.	2.9	64
123	Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 289-297.	2.5	113
124	Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clinical Microbiology and Infection, 2013, 19, E483-E489.	2.8	41
125	Exome Sequencing Identifies Mutations in CCDC114 as a Cause of Primary Ciliary Dyskinesia. American Journal of Human Genetics, 2013, 92, 99-106.	2.6	138
126	ZMYND10 Is Mutated in Primary Ciliary Dyskinesia and Interacts with LRRC6. American Journal of Human Genetics, 2013, 93, 336-345.	2.6	183

#	Article	IF	Citations
127	Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. American Journal of Human Genetics, 2013, 93, 672-686.	2.6	184
128	Tracking lung function on any phone. , 2013, , .		22
129	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 69-75.	0.7	39
130	Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis, 2013, 12, 147-153.	0.3	30
131	ARMC4 Mutations Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry. American Journal of Human Genetics, 2013, 93, 357-367.	2.6	150
132	Opportunities and pitfalls of registry data for clinical research. Paediatric Respiratory Reviews, 2013, 14, 141-145.	1.2	18
133	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 36, 99-105.	0.8	8
134	An Official American Thoracic Society Workshop Report: Optimal Lung Function Tests for Monitoring Cystic Fibrosis, Bronchopulmonary Dysplasia, and Recurrent Wheezing in Children Less Than 6 Years of Age. Annals of the American Thoracic Society, 2013, 10, S1-S11.	1.5	155
135	Standardizing Nasal Nitric Oxide Measurement as a Test for Primary Ciliary Dyskinesia. Annals of the American Thoracic Society, 2013, 10, 574-581.	1.5	222
136	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. European Respiratory Journal, 2013, 42, 527-538.	3.1	49
137	Lung function from infancy to preschool in a cohort of children with cystic fibrosis. European Respiratory Journal, 2013, 41, 60-66.	3.1	21
138	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5â€…years of age. Thorax, 2013, 68, 643-651.	2.7	83
139	Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis. A Pilot Study Using Inhaled Hypertonic Saline. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 456-460.	2.5	147
140	Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis. European Respiratory Journal, 2013, 42, 1545-1552.	3.1	23
141	Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?. European Respiratory Journal, 2013, 42, 844-857.	3.1	36
142	Small airway involvement in cystic fibrosis lung disease: Routine spirometry as an early and sensitive marker. Pediatric Pulmonology, 2013, 48, 1081-1088.	1.0	33
143	Mutations inCCDC39andCCDC40are the Major Cause of Primary Ciliary Dyskinesia with Axonemal Disorganization and Absent Inner Dynein Arms. Human Mutation, 2013, 34, 462-472.	1.1	176
144	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 943-953.	1.0	31

#	Article	IF	Citations
145	Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement. Journal of Neurosurgery: Pediatrics, 2012, 9, 54-63.	0.8	34
146	Mutations ofDNAH11in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. Thorax, 2012, 67, 433-441.	2.7	198
147	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2269-77.	3.8	175
148	Revision Surgeries Are Associated With Significant Increased Risk of Subsequent Cerebrospinal Fluid Shunt Infection. Pediatric Infectious Disease Journal, 2012, 31, 551-556.	1.1	51
149	Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. Journal of Cystic Fibrosis, 2012, 11, 446-453.	0.3	78
150	Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. Journal of Cystic Fibrosis, 2012, 11, 456-457.	0.3	28
151	SpiroSmart. , 2012, , .		154
152	Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 125-134.	1.0	78
153	Lung function distinguishes preschool children with CF from healthy controls in a multiâ€center setting. Pediatric Pulmonology, 2012, 47, 597-605.	1.0	41
154	Analysis of the associations between lung function and clinical features in preschool children with Cystic Fibrosis. Pediatric Pulmonology, 2012, 47, 574-581.	1.0	32
155	Emergence of Oseltamivir-Resistant Pandemic H1N1 in an Immunocompetent Child with Severe Status Asthmaticus. Journal of Asthma, 2011, 48, 572-575.	0.9	2
156	Treatment and Microbiology of Repeated Cerebrospinal Fluid Shunt Infections in Children. Pediatric Infectious Disease Journal, 2011, 30, 731-735.	1.1	40
157	Pulmonary exacerbations are associated with subsequent FEV₁ decline in both adults and children with cystic fibrosis. Pediatric Pulmonology, 2011, 46, 393-400.	1.0	211
158	Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience. Pediatric Pulmonology, 2011, 46, 483-488.	1.0	52
159	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: shortâ€term tolerability, adherence, and safety. Pediatric Pulmonology, 2011, 46, 666-671.	1.0	28
160	Accurate and privacy preserving cough sensing using a low-cost microphone. , 2011, , .		152
161	Bronchiectasis and Pulmonary Exacerbations in Children and Young Adults With Cystic Fibrosis. Chest, 2011, 140, 178-185.	0.4	66
162	Monitoring of Structure and Function in Early Cystic Fibrosis Lung Disease. Pediatric, Allergy, Immunology, and Pulmonology, 2011, 24, 133-137.	0.3	1

#	Article	IF	Citations
163	Appropriate Pediatric Spirometry Reference Equations and Interpretation. Pediatric, Allergy, Immunology, and Pulmonology, 2011, 24, 63-68.	0.3	2
164	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis. JAMA Pediatrics, 2011, 165, 847.	3.6	199
165	Therapeutic bilateral lung lavage in a child with pulmonary alveolar proteinosis. Pediatric Critical Care Medicine, 2010, 11, e28-e31.	0.2	4
166	Return of FEV₁ after pulmonary exacerbation in children with cystic fibrosis. Pediatric Pulmonology, 2010, 45, 127-134.	1.0	120
167	Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. Pediatric Pulmonology, 2010, 45, 107-117.	1.0	161
168	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatric Pulmonology, 2010, 45, 934-944.	1.0	51
169	Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 627-632.	2.5	445
170	Multicenter Evaluation of Infant Lung Function Tests as Cystic Fibrosis Clinical Trial Endpoints. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1387-1397.	2.5	90
171	Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, S73-S93.	0.9	360
172	Cystic Fibrosis Foundation Practice Guidelines for the Management of Infants with Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome during the First Two Years of Life and Beyond. Journal of Pediatrics, 2009, 155, S106-S116.	0.9	176
173	Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials, 2009, 30, 256-268.	0.8	110
174	Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. Pediatric Pulmonology, 2008, 43, 1142-1146.	1.0	13
175	Respiratory Manifestations. , 2008, , 871-887.		1
176	An Overview of Endpoints for Cystic Fibrosis Clinical Trials: One Size Does Not Fit All. Proceedings of the American Thoracic Society, 2007, 4, 299-301.	3.5	48
177	Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report. Pediatrics, 2007, 119, e495-e518.	1.0	139
178	Endpoints for Clinical Trials in Young Children with Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 418-430.	3.5	71
179	Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genetics in Medicine, 2007, 9, 695-704.	1.1	42
180	Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 751-756.	1.0	60

#	Article	IF	Citations
181	Cystic fibrosis pulmonary exacerbations. Journal of Pediatrics, 2006, 148, 259-264.	0.9	139
182	Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. Journal of Pediatrics, 2006, 149, 362-366.	0.9	98
183	Cystic Fibrosis Diseaseâ€"specific Centiles in 2000 and 2005. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1047a-1047a.	2.5	0
184	The Prevalence of Ibuprofen-sensitive Asthma in Children: A Randomized Controlled Bronchoprovocation Challenge Study. Journal of Pediatrics, 2005, 147, 233-238.	0.9	55
185	Overview of published evidence on outcomes with early diagnosis from large US observational studies. Journal of Pediatrics, 2005, 147, S11-S14.	0.9	34
186	Disease-specific Reference Equations for Lung Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 885-891.	2.5	65
187	Update on cystic fibrosis epidemiology. Current Opinion in Pulmonary Medicine, 2004, 10, 510-514.	1.2	42
188	Improved survival among young patients with cystic fibrosis. Journal of Pediatrics, 2003, 142, 631-636.	0.9	116
189	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	2.5	300
190	Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current Opinion in Pulmonary Medicine, 2003, 9, 492-497.	1.2	109
191	Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System. Chest, 2003, 123, 28-36.	0.4	76
192	Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1550-1555.	2.5	255
193	Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology, 2002, 34, 91-100.	1.0	910
194	Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?. Journal of Hospital Infection, 2001, 49, 229-230.	1.4	31
195	Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics, 2001, 139, 359-365.	0.9	265
196	Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. Journal of Pediatrics, 2001, 139, 572-577.	0.9	73
197	Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients. Pediatric Pulmonology, 2001, 31, 227-237.	1.0	57
198	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology, 2001, 32, 356-366.	1.0	361

#	Article	IF	Citations
199	Longitudinal Assessment ofPseudomonas aeruginosain Young Children with Cystic Fibrosis. Journal of Infectious Diseases, 2001, 183, 444-452.	1.9	520
200	Nutritional Effects of Long-Term Gastrostomy Feedings in Children With Cystic Fibrosis. Journal of the American Dietetic Association, 1999, 99, 191-194.	1.3	58
201	Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. , 1999, 28, 321-328.		306
202	Home nebulizer use among patients with cystic fibrosis. Journal of Pediatrics, 1998, 132, 125-131.	0.9	59
203	AEROSOLIZED ANTIBIOTICS FOR BACTERIAL LOWER AIRWAY INFECTIONS. Infectious Diseases in Clinical Practice, 1998, 7, 66-79.	0.1	6
204	Aerosolized Antibiotics for Bacterial Lower Airway Infections. Clinical Pulmonary Medicine, 1997, 4, 101-112.	0.3	7
205	Gender Gap in Cystic Fibrosis Mortality. American Journal of Epidemiology, 1997, 145, 794-803.	1.6	335
206	Evolution of airway microbiology in the infant with cystic fibrosis: role of nonpseudomonal and pseudomonal pathogens. Seminars in Respiratory Infections, 1992, 7, 158-67.	1.3	12
207	Transcriptional and Post-Transcriptional Strategies in Neuroendocrine Gene Expression. , 1988, 5, 317-334.		0
208	Identification of human glucocorticoid receptor complementary DNA clones by epitope selection. Science, 1985, 228, 740-742.	6.0	286